Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Apogee Therapeutics, Inc.NASDAQ: APGE
Other Current Assets · Q2 FY2026 · quarter ended Jun 2026
Other current assets remains negative
Q2 FY2026 other current assets was $0, compared with $963K a year earlier. Over 3 fiscal years it compounded at +119.8% a year.
Context
- Other current assets amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.1 pp from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 605K USD
- Year-over-year change
- -65.3%
- 3-year CAGR
- +119.8%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 605K | -65.3% |
| FY2024 | 2024-12-31 | 1.74M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 57K | — |
Other Current Assets vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 10, against a peer median of +32.3%.
- Other current assets amounts to 0.0% of total assets for APGE, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥192.65M CNY | +682.1% | +126.4% | 4.9% |
| Jun 2026 | $132.64M USD | -5.8% | +61.0% | 12.3% | |
| Mar 2026 | $68M USD | +13.6% | -12.0% | 5.2% | |
| Jun 2026 | $21.8M USD | +48.1% | +931.6% | 2.6% | |
| Sep 2026 | $21.44M USD | +58.7% | +63.9% | 2.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $14.59M USD | +29.7% | — | 2.1% |
| Sep 2026 | $10.1M USD | +14328.6% | +8.0% | 0.6% | |
| Sep 2026 | $8.1M USD | -52.5% | +12.9% | 0.7% | |
| Mar 2026 | $2.13M USD | +32.3% | -17.6% | 0.3% | |
| Jun 2026 | $0 USD | -100.0% | +119.8% | 0.0% | |
| Peer median (excluding APGE) | — | +32.3% | +36.9% | 2.1% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.